Benefiting from robust growth in the Injectables and Generic segments and an acceleration in sales in Europe and ROW, Hikma reported better than expected results in H2 20. The recently-approved Vascepa’s generic is likely to be a key source of growth in the coming years. Moreover, the upcoming launch of Advair Diskus should bolster growth in the mid-term. Success in cracking one of the most difficult drugs, Advair Diskus, reiterates Hikma’s generic manufacturing prowess.

02 Mar 2021
Strong finish to the year; new products hold the key for the future

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong finish to the year; new products hold the key for the future
Hikma Pharmaceuticals Plc (HIK:LON) | 1,981 -217.9 (-0.6%) | Mkt Cap: 4,396m
- Published:
02 Mar 2021 -
Author:
Rishabh Kochar | Amandeep Goyal -
Pages:
3 -
Benefiting from robust growth in the Injectables and Generic segments and an acceleration in sales in Europe and ROW, Hikma reported better than expected results in H2 20. The recently-approved Vascepa’s generic is likely to be a key source of growth in the coming years. Moreover, the upcoming launch of Advair Diskus should bolster growth in the mid-term. Success in cracking one of the most difficult drugs, Advair Diskus, reiterates Hikma’s generic manufacturing prowess.